Its LD50 is well-established, and it has been safely used in clinical studies and multiple human clinical trials.5–7 In cancer cells, 2DG metabolism may affect death receptor (DR) expression and dissociate the Bak-Mcl-1 complex in cells with elevated glycolytic activity.7 Given its established safety, specific effect on only cancer cells, and ability to affect DR expression we were interested in evaluating DR ligands in combination with 2DG to mediate colon cancer-specific apoptosis. Here, MCL1 is linked to cancer.